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The dbl family of oncogenes encodes a large, structur-
ally related, family of growth-regulatory molecules that
possess guanine nucleotide exchange factor activity for
specific members of the Rho family of Ras-related GTP-
ases. We have evaluated matched sets of weakly and
strongly transforming versions of five Dbl family pro-
teins (Lfc, Lsc, Ect2, Dbl, and Dbs) to determine their
ability to stimulate signaling pathways that are acti-
vated by Rho family proteins. We found that the trans-
forming potential of this panel did not correlate directly
with their ability to activate Jun NH2-terminal kinase,
p38/Mpk2, serum response factor, or c-Jun. In contrast,
transient stimulation of transcription from the cyclin
D1 promoter provided a strong correlation with trans-
forming potential, and we found constitutive up-regula-
tion of cyclin D1 protein in Dbl family protein-trans-
formed cells. In addition, we observed that at least two
Dbl family members (Lfc and Ect2) induced changes in
the actin cytoskeleton and exhibited nuclear signaling
profiles that are consistent with a broader range of in
vivo substrate utilization than is predicted from their in
vitro exchange specificities. In summary, although Dbl
family proteins exhibit signaling profiles that are con-
sistent with their in vivo activation of Rho proteins,
stimulation of cyclin D1 transcription is the only activ-
ity that correlates with transforming potential, thus
suggesting that deregulated cell cycle progression may
be important for Dbl family protein transformation.
The Dbl-related proteins are a large family of growth-regu-
latory molecules that function as guanine nucleotide exchange
factors (GEFs)1 and activators of specific members of the Rho
family of proteins (reviewed in Refs. 1 and 2). Mammalian
members of the Dbl family include: Tiam1, a protein involved
in T cell lymphoma invasiveness (3); Bcr, the translocation
partner of the Abl tyrosine kinase in Philadelphia chromosome
positive human leukemias (4); Fgd1, a gene product associated
with the development of Aarskog-Scott syndrome (5); Sos1/2
and RasGRF, two known activators of Ras proteins (6–8); and
the products of the dbl (9), vav (10), ect2 (11), lbc (12), lfc (13),
lsc (14), ost (15), dbs (16), net1 (17), and tim (18) oncogenes.
Typically, the deregulated expression of Dbl family members in
NIH 3T3 fibroblasts results in changes in the morphological
and proliferative properties of these cells, conferring upon
them a highly transformed phenotype (1, 2).
The region of sequence similarity that defines a Dbl family
member consists of an approximately 200 amino acid Dbl ho-
mology (DH) domain, which is novel to this family of proteins,
followed immediately by a pleckstrin homology (PH) domain.
Because most members of the Dbl family share little structural
similarity outside of the tandem DH and PH domains, it is
presumed that these structural motifs contain sequences that
are responsible for the transforming activity. Indeed, recent
studies have shown that the transforming activity of several
Dbl family members is dependent upon the structural integrity
of their DH/PH domain modules (9, 11, 13–16).
Although the mechanism by which the deregulated expres-
sion of a Dbl family member induces a transformed phenotype
has not yet been resolved, there is some evidence that they may
do so through interaction with members of the Rho family of
Ras-related GTPases (19–23). The Rho family of proteins com-
prises at least 12 distinct members including RhoA, RhoB,
RhoC, RhoD, RhoE, RhoG, Rac1, Rac2, CDC42Hs, TC10, and
TTF (24). Rho proteins function as regulated molecular
switches, cycling between a biologically active GTP-bound and
an inactive GDP-bound form (19). They are activated by spe-
cific Rho GEFs that promote the formation of GTP-bound com-
plexes and are inactivated by specific GTPase-activating pro-
teins that stimulate their intrinsic rate of GTP hydrolysis. Dbl
family members have been shown to have GEF activity specific
for Rho family members (15, 25–30), and, in several instances,
this activity has been mapped to the DH/PH domains (30, 31).
Because the constitutive activation of several Rho family mem-
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bers has been shown to be transforming (32–35), Dbl-related
proteins may exert their transforming activity via constitutive
activation of Rho function.
Until recently, Rho family members were thought to be pri-
marily involved in the organization of actin-based cytoskeletal
structures (36–39), and it was generally assumed that these
biological activities were, at least in part, mediating the onco-
genicity of these proteins. CDC42Hs stimulates the formation
of actin microspikes and filopodia, whereas Rac1 causes mem-
brane ruffling and lamellipodia formation, and RhoA regulates
the formation of actin stress fibers. More recently, evidence has
emerged linking Rho family proteins, and by extension the
exchange factors that activate them, to the regulation of gene
expression. First, constitutively activated Rac1 and CDC42Hs
are activators of JNKs (also known as stress-activated protein
kinases) and p38/Mpk2, but not the p42 and p44 ERKs (40–
43). ERKs, JNKs, and p38 proteins represent distinct subsets
of the mitogen-activated protein kinase (MAPK) family. Upon
activation, JNK in turn activates the ATF-2 and Jun nuclear
transcription factors, which can dimerize with other transcrip-
tion factors to stimulate transcription from promoters contain-
ing AP-1 and related DNA sequences (e.g. the c-jun promoter)
(44). Stimulation of p38 activity results in activation of the ATF-2
transcription factor (45). Second, RhoA, Rac1, and CDC42Hs
have been shown to activate SRF (46), which cooperates with
ternary complex factors (Elk-1 and SAP1) and the DNA elements
found in certain promoters such as the c-fos promoter (47). Fi-
nally, a direct link between RhoA, Rac1, and CDC42Hs and cell
cycle progression has been made (42), and this may be mediated
in part by regulating the expression of cyclin D1 (48).
Although the repertoire of signaling pathways that are re-
sponsive to activation by Rho family members is rapidly ex-
panding, relatively little is known of the signaling activities of
their putative regulators, the Dbl-related proteins. Not only is
it unclear whether or not Dbl and Rho proteins can activate the
same signaling pathways, it remains uncertain whether they
transform cells via the same mechanism. The focus-forming
activity of Dbl family members often far exceeds that of acti-
vated mutants of their putative GTPase targets, suggesting
that the biological pathways that are mediated by these two
families of proteins may not precisely overlap (1). However, the
recent determination that several Dbl family members (Fgd1,
Dbl, Ost, and Vav) are potent activators of JNK in transient
assays suggests that this family of oncoproteins, like their
putative GTPase targets, may regulate multiple nuclear sig-
naling pathways (40, 49, 50).
In the present study, we have examined a panel of five Dbl
family members (Ect2, Lfc, Lsc, Dbs, and Dbl) for their ability
to regulate the transduction of signals to the nucleus as meas-
ured by (a) stimulation of JNK and p38/Mpk2 MAPK activity,
(b) stimulation of c-Jun and SRF transcriptional activation,
and (c) regulation of cyclin D1 expression. By utilizing matched
pairs of strongly and weakly transforming mutant derivatives,
we were able to assess whether the strength of the signaling
activity correlated with transforming potential. We observed
that Dbl family proteins typically exhibited a broad range of
signaling activities consistent with their activation of Rho fam-
ily proteins in vivo. Of the different signaling activities ana-
lyzed, stimulation of cyclin D1 transcription was the only ac-
tivity that correlated well with transforming potential, thus
suggesting that deregulated cell cycle progression may be im-
portant for transformation. Finally, we observed that two of the
panel members (Ect2 and Lfc) induced changes in the actin
cytoskeleton, and exhibited signaling profiles that were con-
sistent with a broader range of in vivo substrate utilization
than was predicted from their in vitro GEF specificity.
EXPERIMENTAL PROCEDURES
Expression Vectors and Reporter Plasmids—The pCTV3H, pCTV3HA,
and pAX142 mammalian expression vectors have been described pre-
viously (13). Initially, constructs that place an in-frame epitope from
the hemagglutinin (HA) protein of influenza virus at the NH2 termini of
the various Dbl family members were made by subcloning into the HpaI
site of pCTV3HA as described below. All constructs were then digested
with MluI/SunI and shuttled into corresponding sites in the pAX142
mammalian expression vector. Unless otherwise indicated, all assays
were performed using the pAX142 derivatives where expression is
controlled by the EF-1a promoter. All fragments that were synthesized
by polymerase chain reaction were sequenced in their entirety to ensure
that only specified mutations had occurred.
Lfc-D13HA, Lfc-P3HA, Lfc-D6, and Lfc-D7 have been described pre-
viously (13). Lfc-D7HA was made by isolating the MluI/SunI fragment
from Lfc-D7, filling in the MluI site with T4 DNA polymerase, and
inserting the fragment into pCTV3HA digested with HpaI/SunI. Lfc-
D6HA was made by replacing the FspI/SunI fragment of Lfc-D13HA
with the FspI/SunI fragment of Lfc-D6.
Dbs-HA1 was made by shuttling the FspI/SunI fragment of the
TL19–10c2 cDNA (16) into pCTV3HA cut with HpaI/SunI. Dbs-HA2
was made by isolating the NsiI fragment from TL19–10c2, blunting the
fragment with T4 DNA polymerase, and ligating it to pCTV3HA di-
gested with HpaI. Dbs-HA6 was made by replacing the FspI/SunI
fragment of Dbs-HA2 with the FspI/Sun1 fragment of Dbs-HA1.
Ect2-HA1 and Ect2-HA2 were made by isolating the XbaI (HA1) and
XbaI/XhoI (HA2) fragments from the TL17–5cA3 cDNA (51), filling in
the ends of these fragments with T4 DNA polymerase, and ligating
them to pCTV3HA cut HpaI. Ect2-HA3 was made by replacing the
PflMI/SunI fragment of Ect2-HA1 with the PflMI/SunI fragment from
TL17–5cA3.
As an initial step in constructing HA-tagged Dbl constructs, the
BamHI fragment was isolated from pZIP-proto-dbl (52), blunted with
T4 DNA polymerase and ligated to pCTV3H digested with HpaI
(pCTV3H-proto-dbl). In order to make Dbl-HA1, primers Dbl1 and Dbl2
(Dbl1: ACG GAT CCA CGC GTC CCG GGC CAC CAT GGA CAA TGG
CAA TAG CTT G; Dbl2: ACG GAT CCA TGC ATA GAA TCA TTA AC)
were used to amplify a 609-base pair dbl fragment using pCTV3H-
proto-dbl as template. This fragment was ligated into the EcoRI site of
pBS-SK1 (Stratagene). After sequencing, the fragment was isolated
from the vector using SmaI and ligated to pCTV3HA digested with
HpaI (Dbl-HA3). The FspI fragment from pCTV3-proto-dbl was then
isolated and ligated into the FspI site of Dbl-HA3. In order to make
Dbl-HA2, primers Dbl2 and Dbl3 (Dbl3: ACG AAT TCA CGC GTC CCG
GGC CAC CAT GGC AGA AGC AAA TCC CCG GAG A) were used to
amplify a 2064-base pair fragment using pCTV3H-proto-dbl as tem-
plate. This fragment was ligated into the EcoRI site of pBS-SK1. Fol-
lowing sequencing, the fragment was isolated using EcoRV/SmaI and
ligated to pCTV3HA digested with HpaI (Dbl-HA4). Dbl-HA2 was made
by replacing the Psp1406I/SunI fragment of Dbl-HA4 with the
Psp1406I/SunI fragment from pCTV3H-proto-dbl.
Lsc-D7 and Lsc-D3 have been described previously (14). Lsc-D7HA
was made by isolating the HpaI/SunI fragment from Lsc-D7 and ligat-
ing into pCTV3HA cut HpaI/SunI. This construct was then cut with
MluI/HpaI, and a linker was inserted to remove the termination codon
within the HpaI site. Lsc-D3HA was made by replacing the FspI/SunI
fragment of Lsc-D7HA with the FspI/SunI fragment from Lsc-D3.
Reporters for the analysis of cyclin D1 activity (CD1(-963)-Luc),
c-Jun activity (5XGal-Luciferase and Gal4-Jun-(1–254)), and SRF ac-
tivity ((SREm)2-Luc) have been described previously (48, 53, 54). FLAG
epitope-tagged expression vectors for JNK1 and p38/Mpk2, and the
bacterial expression vectors encoding GST-ATF2 and GST-Jun-(1–79)
were provided by M. Karin. pCMVnlac encodes the sequences for the
b-galactosidase gene under the control of the CMV promoter (provided
by J. Samulski).
Cell Culture, Transfection, and Transformation Assays—COS-7 and
NIH 3T3 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM; high glucose) supplemented with 10% fetal bovine or newborn
calf serum, respectively. Transfection of COS-7 cells was achieved with
the LipofectAMINE reagent (Life Technologies, Inc.) as described by the
manufacturer. Thirty h after transfection, the medium was changed to
DMEM containing 0.5% fetal bovine serum, and after 14 h of incubation
lysates were prepared as described previously (45). NIH 3T3 cells were
transfected by calcium phosphate co-precipitation as described previ-
ously, allowed to recover for 30 h, and starved in DMEM with 0.5%
newborn calf serum for 14 h before lysate preparation (55–57). Focus-
formation assays were performed in NIH 3T3 cells exactly as described
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(55). Cognate empty vectors of each plasmid were employed as controls.
NIH 3T3 cell lines that stably express the pCTV3HA derivatives of
Dbl-HA1, Dbs-HA6, Ect2-HA3, and Lsc-D7HA were generated by cal-
cium phosphate co-precipitation, followed by selection for 14 days in
growth medium supplemented with hygromycin B (200 mg/ml).
Transient Expression Reporter Gene Assays—Analysis of luciferase
expression in transiently transfected NIH 3T3 cells was performed as
described using enhanced chemiluminescent reagents and a Monolight
2010 luminometer (Analytical Luminescence, San Diego CA) (56). b-Ga-
lactosidase activity in transiently transfected NIH 3T3 cells was deter-
mined exactly as described (58). All assays were performed in duplicate.
Data shown are from one experiment performed in duplicate (6 S.E.),
and are representative of at least three independent experiments.
Immunoprecipitation and in Vitro Kinase Assays—JNK1 and p38/
Mpk2 activity was analyzed in COS-7 cells following transfection of
FLAG-tagged JNK1 or p38/Mpk2 and the various tester constructs.
Cells were transfected in 100-mm plates and starved for 14 h, and then
lysates were collected in 1 ml of lysis buffer containing protease and
phosphatase inhibitors (45). JNK1 or p38/Mpk2 was immunoprecipi-
tated with anti-FLAG (M2; Kodak/IBI) antibody as indicated, and the
kinase activity was measured using 2 mg of GST-Jun-(1–79) or GST-
ATF2-(1–254), respectively, as substrate. In vitro kinase reactions were
carried out for 20 min at 30 °C, and stopped with 23 SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) loading buffer. Proteins were
fractionated on 12.5% SDS-PAGE and blotted to Immobilon (Millipore).
Blots were dried and exposed to film for 1–3 h and then subjected to
quantitation on a PhosphorImager (Molecular Dynamics). Blots were
subsequently probed with anti-FLAG antibody (M2; Kodak/IBI) to vi-
sualize expression of the p38/Mpk2 or JNK1 construct. A 1/10 volume of
the lysate used in the immunoprecipitations was fractionated on 12.5%
SDS-PAGE and probed with anti-HA antibody (BAbCO) to visualize
Dbl family protein expression levels in the lysate. Following incubation
with horseradish peroxidase-labeled anti-mouse secondary antibodies,
Western blots were developed with ECL reagents (Amersham Pharma-
cia Biotech).
The abundance of cyclin D1 protein in stably selected cell lines was
determined by Western blot analysis as described previously (53) using
a monoclonal cyclin D1 antibody (HD11; Santa Cruz Biotechnology).
Membranes were incubated with horseradish peroxidase-labeled anti-
mouse secondary antibodies, and protein was visualized with ECL
(Amersham Pharmacia Biotech). Blots were subsequently probed with
an anti-a-tubulin antibody (5H1; Ref. 59) to establish an internal con-
trol for protein levels.
Analysis of Actin Stress Fiber and Lamellipodia Formation—Analy-
sis of actin stress fibers and lamellipodia was performed as described
previously (60). Briefly, porcine aortic endothelial (PAE) cells were
injected in the nucleus with pAX142-lfc-D7HA, pAX142-lfc-D13HA,
pAX142-ect2-HA3, or pAX142-ect2-HA2 (25 mg/ml). Subsequently, cells
were starved in serum-free growth medium for 12–14 h and fixed in 4%
formaldehyde as described previously (60). Expressed HA-tagged Dbl
proteins were visualized by indirect immunofluorescence using anti-HA
antibodies, and polymerized actin was stained with phalloidin.
RESULTS
Functional Expression of Epitope-tagged Dbl Family Mem-
bers—Typically, NIH 3T3 cells that have been transformed by
Dbl family members form foci comprising rounded, piled-up,
non-refractile cells and promote tumor growth when injected
subcutaneously into nude mice (1). To assess the relationship
between this transforming activity and the activation of nu-
clear signaling pathways, matched pairs of strongly and
weakly transforming derivatives of Ect2, Lfc, Lsc, Dbl, and Dbs
were constructed in the mammalian expression vector pAX142.
The weakly transforming derivatives were selected from large
panels of mutants for each family member, and the criteria
used for selection was high level of expression relative to their
strongly transforming counterparts. For Dbl, we utilized the
weakly transforming, full-length versions of the protein,
whereas for Lfc, Lsc, Dbs, and Ect2, weakly transforming de-
rivatives were generated by deleting portions of their respec-
tive PH domains. Additional Dbs, Lfc, and Ect2 variants were
included in the panel that exhibited intermediate levels of
transforming activity. All proteins tested retained intact DH
domains and most retained at least some biological activity as
evidenced by low, but reproducible focus-forming activity (Fig.
1A). All proteins also contained an NH2-terminal HA epitope
tag to verify that each exhibited detectable levels of expression
in transient assays utilizing COS-7 cells (Figs. 2 and 3).
Initially, all members of the panel were assayed for trans-
forming potential in an NIH 3T3 focus-formation assay (Fig.
1A). Transforming activity varied by as much as 200-fold
among family members, and was due to intrinsic levels of
transforming activity rather than to variability in levels of
expression of the constructs (Figs. 2 and 3). For example, the
strongly transforming versions of Ect2, Dbl, and Dbs showed
the highest focus-forming activity (.6 3 103 focus-forming
units/pmol) and were more than 100-fold higher than their
weakly transforming counterparts. Interestingly, two distinct
focus morphologies were observed among panel members (Fig.
1B), suggesting that the transforming pathways utilized by Dbl
family proteins may differ. Dbs and Dbl caused foci that were
characteristically large and diffuse, whereas Ect2, Lfc, and Lsc
FIG. 1. Domain structure and focus-forming activities of
epitope-tagged derivatives of Dbl family members. A, the domain
structure of each Dbl family member is shown in the upper line of each
matched set of derivatives (drawn approximately to scale), and the lines
below indicate the regions of the protein included in predicted transla-
tional products of the various cDNA constructs. The tandem DH/PH
domain modules are indicated by shaded boxes. All panel members have
been tested previously for in vitro exchange activity for RhoA, Rac1, and
CDC42Hs (1), and a summary of these results is indicated in parenthe-
ses. All members of the panel were assayed for transforming potential
in an NIH 3T3 cell focus-formation assay. NIH 3T3 cells were trans-
fected with 3 mg of the indicated expression vector, and cultured for 14
days before foci were counted. The data are expressed as foci per
picomole of DNA and represent the average of three independent ex-
periments. B, morphology of transformed foci of cells induced in NIH
3T3 cells by transfection of Dbl-HA1 and Ect2-HA3. NIH 3T3 cells were
transfected with 3 mg of DNA as described above, and foci were photo-
graphed after 14 days.
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foci were substantially smaller, more compact, and formed
networks of interconnected foci that appeared to be of clonal
origin.
Activation of JNK1 by Dbl Family Proteins—The JNK family
of MAPKs comprises closely related enzymes that are activated
by cellular stress (61). The recent observation that several
members of the Rho (CDC42Hs, Rac1) and Dbl (Ost, Dbl, Fgd1,
and Vav) families can activate the JNK signaling pathway
prompted us to explore whether JNK activation by Dbl-related
proteins correlates with their transforming potential. We ex-
amined strongly and weakly transforming derivatives of five
Dbl family members (Lfc, Lsc, Dbl, Dbs, and Ect2) for their
ability to activate JNK1 in an in vitro kinase assay (Fig. 2).
This panel consisted only of Dbl family proteins that are known
to be transforming in NIH 3T3 cells and for which the in vitro
exchange specificities for RhoA, Rac1, and CDC42Hs have been
determined (Fig. 1A).
When transfected into COS-7 cells, all members of the panel
were detectably expressed at roughly equivalent levels as
judged by Western blot analysis with the anti-HA antibody
(Fig. 2, lower panel). Immunocomplex kinase assays using
GST-Jun as a substrate indicated that transforming deriva-
tives on the panel consistently induced 1.8–23-fold increases in
the in vitro kinase activity of JNK1 (Fig. 2, upper panel; sum-
marized in Table I). Although this activity was generally im-
paired among the more weakly transforming variants, the de-
gree of impairment did not always reflect relative transforming
potencies. For example, Lfc-D7HA exhibited a higher level of
activation of JNK1 than the more strongly transforming Lfc-
D6HA, and there was no correlation between JNK1 activation
and transforming activity for the three Ect2 variants. A com-
parison between the different family members revealed similar
inconsistencies. For example, Ect2-HA3 was 65-fold more effi-
cient than Lfc-D7HA at inducing foci but showed consistently
lower levels of JNK1 activity (4.7-fold versus 16.1 fold). We
conclude that the transforming potency of a Dbl family member
is not a reflection of its ability to stimulate JNK1 activity.
Activation of p38/Mpk2 by Activated Dbl Family Proteins—
Our determination that Dbl family members consistently cause
activation of JNK prompted us to examine whether Dbl family
proteins could activate other MAPK-regulated signaling path-
ways. p38/Mpk2 forms an additional branch of the mammalian
MAPK family that is regulated by many of the same upstream
stimuli as JNK and for which activity can be regulated by Rho
family GTPases (43). To examine the effect of Dbl family pro-
teins on p38/Mpk2 activity, we co-transfected the panel mem-
bers with a FLAG epitope-tagged p38/Mpk2 expression vector.
Immunocomplex kinase assays using GST-ATF2 as a substrate
indicated that transforming derivatives from the panel consis-
tently induced 2.5–4-fold increases in the in vitro phosphoryl-
ating activity (Fig. 3). Although the more weakly transforming
derivatives were consistently impaired in p38 activation, the
degree of impairment did not always reflect the observed dif-
ferences in transforming activity. For example, Dbl-HA1 and
Dbl-HA2 exhibited comparable levels of p38 activation (2.9-
versus 2.5-fold) yet differed by over 150-fold in focus-forming
activity (Fig. 1A). As was the case with JNK1 activation, a
comparison between the various family members on the panel
did not reveal a good correlation between transforming potency
and p38 activation. Lsc-D7HA and Dbl-HA1 showed similar
levels of p38 activation (2.6- versus 2.9-fold); however, Dbl-HA1
is almost 200-fold more efficient than Lsc-D7HA at inducing
foci. Thus, although Dbl family members share a common
ability to activate p38, we have not seen a good correlation
FIG. 2. Activation of JNK1 by Dbl family proteins. COS-7 cells
were transfected with a plasmid expressing FLAG epitope-tagged JNK1
together with the indicated HA epitope-tagged Dbl family derivative or
the cognate empty vector (pAX142). Cells were serum-starved for 14 h,
and JNK1 was immunoprecipitated from lysates for analysis in im-
mune complex kinase assays with GST-Jun-(1–79) as substrate. Kinase
reactions were subjected to SDS-PAGE, transferred to Immobilon fil-
ters, and exposed to film (top panel). Phosphorylation of GST-Jun was
determined by phosphoimage analysis, and is expressed relative to the
level obtained in JNK11vector-transfected cells (Fold). Membranes
were subsequently probed with anti-FLAG antiserum to visualize
JNK1 levels in the immunoprecipitates (middle panel). GEF levels were
determined by Western blotting and probing with antibodies directed
against the HA epitope (aHA) (lower panel). Data shown are represent-
ative of three independent experiments.
FIG. 3. Activation of p38/Mpk2 MAPK by Dbl family proteins.
COS-7 cells were transfected with an expression vector encoding FLAG
epitope-tagged p38/Mpk2 along with the indicated member of the panel.
Cells were serum-starved for 14 h, and p38/Mpk2 was immunoprecipi-
tated from lysates for analysis in complex kinase assays with GST-
ATF2 as substrate (top panel). Phosphorylation of ATF2 was measured
by phosphoimage analysis as in Fig. 2. Membranes were subsequently
probed with anti-FLAG antiserum to visualize p38/Mpk2 levels in the
immunoprecipitates (middle panel). GEF levels were determined by
Western blotting as described in Fig. 2 (lower panel). Data shown are
representative of three independent experiments.
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between p38 activation and transforming potency.
Stimulation of c-Jun Transcriptional Activity by Dbl Family
Members—The efficient activation of the JNK pathway by Dbl
family members should result in stimulation of c-Jun tran-
scriptional activity. Indeed, derivatives of Dbl family members
exhibited strong stimulation of the transcriptional activity of
Gal4-Jun-(1–254), a fusion protein that retains the c-Jun NH2-
terminal activation domain (Fig. 4). Not surprisingly, strong
activation (10–20-fold) was observed among those proteins that
exhibited greatest JNK activity (Lfc, Dbs, and Dbl; Table I). We
did not see a good correlation between c-Jun activation and the
transforming activity of our panel members. For example, al-
though transforming versions of Lfc showed moderate activa-
tion of the Gal4-c-Jun reporter (10-fold), greatest activation
was observed with the non-transforming PH domain minus
derivative Lfc-D13HA (.20-fold), suggesting that transcrip-
tional activation of c-Jun is not sufficient to induce Lfc-medi-
ated transformation. Taken together, our results suggest that
JNK and c-Jun transcriptional activation is not sufficient to
account for the transforming activity associated with the var-
ious Dbl family members on the panel.
Stimulation of SRF Transcriptional Activity by Dbl Family
Members—Constitutively activated mutants of Rho, Rac, and
CDC42Hs have been shown to be strong transcriptional acti-
vators of SRF function, although the signaling pathways uti-
lized for this activation have not yet been determined (46). All
transforming Dbl family members on the panel exhibited mod-
erate to strong activation of SRF (50–720-fold; Fig. 5). How-
ever, SRF activation correlated poorly with focus-forming ac-
tivity. For example, although Dbl-HA2 showed a 500-fold lower
focus-forming activity than Dbl-HA1, this was not reflected in
a correspondingly lower activation of SRF. Similarly, the po-
tent focus-forming activity of Ect2 is not reflected in its ability
to stimulate SRF activity. Clearly, strong SRF activation alone
is not sufficient to cause potent focus-forming activity, nor is
low SRF activation predictive of weak focus-forming activity.
Interestingly, the degree of SRF activation showed a good
correlation with focus morphology and GEF specificity (Table
I). Dbl family proteins that induce large, diffuse foci, and that
have a broader range of in vitro substrate utilization (Dbl and
Dbs), exhibited characteristically high levels of SRF activity.
This result is in accordance with a previous report that specific
Rho family proteins (including CDC42Hs and RhoA) can acti-
TABLE I
Properties of Dbl family guanine nucleotide exchange factors
Relative activities are based on the data sets shown in the manuscript
and are representative of experiments performed in triplicate.
Protein Relative focus-formationa Gal-Jun
b Jnkc p38d SRFe Cyclin D1f
Dbs-HA6 6926.4 11 111 11 111 111
Dbs-HA1 575.1 1 111 1 111 11
Dbs-HA2 0.0 2 2 1/2 2 1/2
Dbl-HA1 12,997.6 111 111 1 1111 111
Dbl-HA2 82.9 1 1/2 1 111 1
Ect2-HA3 7711.0 1/2 1 11 11 111
Ect2-HA1 61.6 1/2 2 1/2 11 11
Ect2-HA2 7.9 2 1/2 1/2 1 1/2
Lsc-D7-HA 59.7 1/2 2 1 11 1/2
Lsc-D3-HA 1.7 2 2 1 2 2
Lfc-D6-HA 203.8 11 11 1 11 11
Lfc-D7-HA 115.0 11 111 1 1 1/2
Lfc-D13-HA 1.0 111 1/2 1/2 1/2 1/2
a Relative activity in NIH 3T3 focus-formation assays. Data are cal-
culated as foci per picomole of DNA.
b In vivo activation of Gal-Jun transcriptional activity. Fold activa-
tion relative to vector only: 2, ,2-fold; 1/2, 2–5-fold; 1, 5–7.5-fold; 11,
7.5–15-fold; 111, 15–30-fold.
c Activation of JNK1 in transiently transfected COS-7 cells. -Fold
activation relative to vector only control: 2, ,2-fold; 1/2, 2–4-fold; 1,
5–8-fold; 11, 8–12-fold; 111, .12-fold.
d Activation of p38 in transiently transfected COS-7 cells. -Fold acti-
vation relative to vector only control: 2, ,1.5-fold; 1/2, 1.5–2-fold; 1,
2–3-fold; 11, .3-fold.
e In vivo activation of transcription from an SRF-dependent promoter
upstream of the luciferase gene. -Fold activation relative to vector only
control: 2, ,2-fold; 1/2, 2–5-fold; 1, 5–20-fold; 11, 20–100-fold; 111,
100–500-fold; 1111, .500-fold.
f In vivo activation of transcription from the cyclin D1 promoter
upstream of the luciferase gene. -Fold activation relative to vector only
control: 2, ,2-fold; 1/2, 2–5-fold; 1, 5–10-fold; 11, 10–25-fold; 111,
25–50-fold.
FIG. 4. Activation of c-Jun by Dbl family GEFs in NIH 3T3 cells.
NIH 3T3 cells were transiently transfected with Gal4-c-Jun-(1–254),
composed of the yeast Gal4 DNA binding domain fused to the amino-
terminal activation domain of the c-Jun protein (0.25 mg), the reporter
construct 5XGal-luciferase (2.5 mg), and pCMVnlac (0.5 mg) as an in-
ternal control for transfection efficiency and toxicity. This reporter
system provides a functional readout for total cellular JNK activity.
Cells were co-transfected with empty expression vector or the indicated
panel member (0.5 mg), cultured for 30 h, and then serum-starved (0.5%
calf serum) for 14 h before extract preparation. Luciferase and b-galac-
tosidase activity was measured and expressed as -fold activation rela-
tive to the level of activation seen with the vector control. Luciferase
activity was then standardized relative to b-galactosidase activity. Data
shown are representative of three independent experiments for each
construct performed in duplicate.
FIG. 5. Activation of SRF by Dbl family proteins in NIH 3T3
cells. Cells were co-transfected as in Fig. 4 with the reporter constructs
(SREm)2-luciferase to measure GEF activation of SRF, and pCMVnlac.
Data are calculated and presented as in Fig. 4. Data shown are repre-
sentative of three independent experiments performed in duplicate for
each derivative.
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vate SRF via independent pathways (46). It also implies that
the activation of SRF-mediated signaling pathways may con-
tribute to the observed differences in focus morphology.
Stimulation of Cyclin D1 Expression by Dbl Family Mem-
bers—Both Ras and Rho family proteins have an essential role
in cell cycle progression through G1, in part, by stimulating the
expression of cyclin D1 (42, 48, 53, 62, 63). Because Dbl and
Rho family members appear to activate many of the same
signaling pathways, we evaluated the possibility that Dbl fam-
ily proteins may also stimulate cyclin D1 expression. For these
analyses, we utilized a reporter plasmid where luciferase gene
expression was controlled by the cyclin D1 promoter (53). Like
activated Rho proteins, all the transforming Dbl family pro-
teins on the panel stimulated cyclin D1 promoter expression
(Fig. 6A). Promoter stimulation correlated with transforming
activity both when comparing different Dbl family members
and when comparing proteins impaired in transformation with
their parental derivatives (Table I). The clear correlation be-
tween cyclin D1 transcription and transforming activity impli-
cates the deregulation of cell cycle control as a contributing
mechanism to the transforming activity of Dbl family members.
To confirm that stimulation of the cyclin D1 promoter in a
transient reporter assay reflects the constitutive up-regulation
of the cyclin D1 protein in Dbl family protein transformed cells,
cyclin D1 levels were measured in NIH 3T3 cell lines that had
been stably selected with transforming derivatives of several
Dbl family members. In all panel members examined, 4–15-
fold increases in cyclin D1 protein expression were observed
when compared with vector controls (Fig. 6B). These differ-
ences could not be attributed to overall variation in protein
expression among the various cell lines and suggest that ele-
vated cyclin D1 expression may be required to maintain the
transformed state.
Ect2 and Lfc Induce Lamellipodia and Actin Stress Fiber
Formation in PAE Cells—Two members of the panel (Ect2 and
Lfc) exhibited signaling profiles that were consistent with a
broader range of substrate utilization than was predicted by
their in vitro exchange activity. For example, the strong acti-
vation of JNK1 by Lfc-D7HA was unexpected (16.1-fold) be-
cause in vitro data suggest that Lfc is a specific activator of
RhoA (29) and RhoA does not activate JNK1 in COS-7 cells (40,
41). The in vitro exchange assays that have been performed
with Ect2 have failed to detect any catalytic activity and it has
been proposed that Ect2 may transform cells by forming non-
productive interactions with endogenous Rho proteins (11).
However, in this current study, ect2 exhibits a signaling profile
(activation of JNK1 and SRF) that is more consistent with a
productive interaction with Rho proteins in vivo. To address
these apparent inconsistencies, we examined the effects of ex-
pressing Lfc and Ect2 on the organization of the actin cytoskel-
eton. It has been shown previously that activated derivatives of
RhoA, Rac1, and CDC42Hs have profound, yet discrete effects
on various actin cytoskeletal structures (36–39). CDC42Hs
mediates the induction of actin microspikes and filopodia,
whereas Rac1 causes membrane ruffling and lamellipodia for-
mation, and RhoA regulates the formation of actin stress fibers
(39). In mouse Swiss 3T3 cells, the assembly of these structures
involves a cascade in which CDC42Hs activates Rac1, which in
turn activates RhoA (39). For our analysis, we injected expres-
sion plasmids encoding strongly and weakly transforming de-
rivatives of Ect2 and Lfc into PAE cells. The transforming
derivatives of Ect2 and Lfc (Ect2-HA3 and Lfc-D7HA) induced
actin stress fiber and lamellipodia formation consistent with
activation of RhoA and Rac1 (Fig. 7). Interestingly, the stress
fibers induced by Ect2 expression are distributed parallel to the
cell membrane, which is distinct from the distribution seen in
cells that express Lfc or an activated derivative of RhoA (39).
The weakly transforming derivatives Lfc-D13HA and Ect-HA3
induced only marginal stress fiber formation and no lamellipo-
dia (not shown). These results suggest that both Ect2 and Lfc
can activate multiple Rho family proteins in vivo and is con-
sistent with our observations on nuclear signaling by these
proteins.
DISCUSSION
Dbl family proteins are one of the largest known families of
transforming proteins (.20 members), yet relatively little is
known of the signaling pathways that they activate (1, 2).
Whereas the involvement of several family members in cy-
toskeletal architecture (26, 50) and in the stimulation of JNK
activity has been documented (40, 49, 50), the relevance of
these biological activities to cellular transformation has not yet
been determined. In this current study, we have examined
matched sets of weakly and strongly transforming variants of
five Dbl family proteins for their ability to activate the JNK
and p38/Mpk2 MAPKS, to activate the SRF and c-Jun tran-
scription factors, and to stimulate transcription from the cyclin
D1 promoter. A consistently high level of activation was ob-
served in all assays thus establishing an important link be-
tween Dbl family protein activity and the activation of nuclear
signaling pathways. Although weakly transforming derivatives
of Dbl family members were often impaired in their ability to
FIG. 6. Up-regulation of cyclin D1 expression by Dbl family
GEFs. A, NIH 3T3 cells were co-transfected with the human cyclin D1
luciferase reporter construct, pCMVnlac, and the indicated Dbl family
derivative. Data are calculated and presented as in Figs. 4 and 5. Data
shown represent the average of at least three independent experiments
performed in duplicate. B, NIH 3T3 cell lines that stably express the
indicated Dbl family GEFs were plated at 106 cells/15-cm plate and then
cultured for 24 h in growth medium supplemented with 10% calf serum.
Cells were then serum-deprived (0.5% calf serum) for 24 h and lysates
collected. The abundance of cyclin D1 protein (lower panel) was deter-
mined by Western blot analysis using a monoclonal cyclin D1 antibody
(HD11; Santa Cruz Biotech), followed by phosphoimage analysis. The
cyclin D1 expression levels were normalized to a-tubulin expression
levels (upper panel) and then expressed relative to the level observed in
vector-transfected cells (Fold).
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stimulate nuclear signaling pathways, only in the case of cyclin
D1 activation were we able to establish a consistent correlation
between a signaling event and transforming potential.
We have demonstrated a role for Dbl family proteins in the
activation of MAPK signaling pathways in two ways. First, we
showed that activated derivatives of most panel members stim-
ulated the catalytic activities of JNK1 and p38/Mpk2 in tran-
sient transfection assays thus extending the repertoire of
MAPKs that are responsive to Dbl proteins to include p38/
Mpk2. We then established that activated derivatives of Dbl
family members are able to induce c-Jun transcriptional acti-
vation. However, whereas it is now clear that many activated
derivatives of Dbl family members can potently stimulate
MAPK-mediated signaling pathways, the contribution of these
pathways to cellular transformation remains unclear. Al-
though several recent reports have suggested that JNK activity
is required for full Bcr/Abl- and Ras-induced transformation
(42, 54, 64, 65), we have observed that at least one potently
transforming Dbl family member, Ect2, shows relatively weak
activation of JNK and c-Jun whereas a non-transforming de-
rivative of Lfc (Lfc-D13HA) exhibited strong activation of the
c-Jun reporter. We observed similar inconsistencies when
measuring p38/Mpk2 activation. Oncogenic Dbl had the high-
est focus-forming activity on the panel (more than 150-fold
higher than its weakly transforming counterpart), yet both Dbl
derivatives exhibited equivalent, weak activation of p38/Mpk2.
Collectively, these observations suggest that JNK and p38/
Mpk2 signaling is not always required for Dbl family protein-
mediated transforming activity. These results are in accord-
ance with our recent observation that a dominant-inhibitory
version of SEK MAPK is a strong inhibitor of c-Jun transcrip-
tional activation in NIH 3T3 cells but fails to block Dbl and Dbs
transforming activity.2
Our demonstration that Dbl family proteins can potently
stimulate transcriptional activation of SRF presents an alter-
native nuclear signaling pathway through which Dbl trans-
forming activity could be mediated. However, as was the case
with JNK and p38 activation, we did not observe a good corre-
lation between transforming potency and SRF activation, thus
suggesting that this does not represent a proliferative pathway
that is utilized by Dbl family members. Although no Dbl family
member has been shown previously to stimulate SRF activa-
tion, activated mutants of Rho, Rac, and CDC42Hs are all
strong activators of SRF (41, 46). Essentially nothing is known
concerning the signaling pathway through which Rho and Dbl
family proteins stimulate SRF, yet the involvement of these
two biochemically related families implies a common mecha-
nism of activation. Interestingly, exchange factors for which
the exchange specificities included CDC42Hs and RhoA (Dbl
and Dbs) showed the highest SRF activation regardless of
relative transforming potencies. These observations are in ac-
cordance with a recent report that CDC42Hs and RhoA acti-
vate SRF reporters via distinct signaling events (46) and sug-
gest that the strong activation of SRF by Dbs and Dbl may be
a consequence of the additive effects of multiple, Rho-mediated
signaling pathways.
Previous studies have shown that both Ras and Rho family
function are necessary for cell cycle progression through G1 (42,
66, 67). Although the pathways that are utilized for this func-
tion are not yet known, the ability of Ras and Rac1 to stimulate
expression of cyclin D1 would provide one such mechanism (48,
53, 62, 63, 68). cyclin D1 levels are up-regulated in cells trans-
formed by Ras (62, 69), and Ras and Rac1 can stimulate tran-
scription from the cyclin D1 promoter (48, 53, 68). Thus, it is
possible that Ras regulates G1 progression via pathways me-
diated by Rho proteins and/or their Dbl family regulators.
Consistent with this, we have demonstrated that Dbl family
proteins are also strong activators of transcription from the
cyclin D1 promoter and that the extent of their activation
corresponds precisely with the strength of transforming activ-
ity. In addition, we have observed elevated levels of cyclin D1
expression in stable cell lines that express transforming deriv-
atives of Dbl family members. This is a clear demonstration
that deregulated Dbl family protein activity may impinge di-
rectly on progression through the cell cycle and suggests at
least one mechanism by which the growth properties of trans-
formed cells could be altered.
The pathway by which Dbl family members are activating
cyclin D1 is unclear. The promoter fragment contains an AP-1
site (at 2954 of the human sequence) where activated Jun may
cause stimulation of cyclin D1 expression, and a distinct region
that is sensitive to stimulation by the ERK MAPKs (53). How-
ever, our current observation that Dbl family members such as
2 J. K. Westwick, R. J. Lee, Q. T. Lambert, M. Symons, R. G. Pestell,
C. J. Der, and I. P. Whitehead, unpublished observations.
FIG. 7. Lfc and Ect2 induce the for-
mation of lamellipodia and stress fi-
bers. PAE cells were microinjected with
expression constructs encoding HA
epitope-tagged Lfc-D7HA and Ect2-HA3.
The actin cytoskeleton and expressed pro-
teins were visualized, respectively, by
phalloidin and indirect immunofluores-
cence using anti-HA antibodies. The two
side panels show higher magnification
and longer exposure micrographs to high-
light the lamellipodia. The arrow indi-
cates a broad lamellipodium induced by
Lfc; arrowheads indicate the narrower la-
mellipodia caused by expression of Ect2.
Bars indicate 10 nm.
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Ect2 showed low levels of JNK and Jun activation, while ex-
hibiting maximal levels of cyclin D1 activity, argues that at
least some Dbl family members may not be utilizing JNK-
mediated pathways to induce cyclin D1 expression.
Our observation that Dbl family members can stimulate both
p38/Mpk2 activation and expression from the cyclin D1 pro-
moter differs from a recent report in which activation of p38/
Mpk2 antagonized expression from a cyclin D1 promoter frag-
ment (68). One possible explanation for this discrepancy is that
that the promoter fragment that they used lacked the AP-1-
responsive element through which p38/Mpk2 or JNK may be
causing stimulation of cyclin D1 expression. In support of this,
we recently demonstrated that mutations within this AP-1 site
significantly impaired the responsiveness of our reporter con-
struct to Rac1 activation (48).
There is considerable in vitro biochemical evidence that
many of the Dbl-related proteins are regulatory molecules for
the Rho family of Ras-related GTPases (1, 2). Many Dbl family
proteins exhibit in vitro guanine nucleotide exchange activity
toward Rho family members and presumably elevate the level
of active GTP-bound molecules in the cell. In addition to their
well characterized biochemical interaction with Dbl proteins,
Rho family members oncogenically transform mammalian fi-
broblasts (32–35), and induce alterations in actin-based cy-
toskeletal structures when injected into Swiss 3T3 cells (36–
39). Rho family members have also been shown to be potent
stimulators of JNK and p38/Mpk2 activity (40, 41), of c-Jun and
SRF transcriptional activity (41, 46), and of cyclin D1 expres-
sion (48). Our observation that Dbl family proteins stimulate
the same transcriptional response elements as Rho proteins
strengthens the correlation between Dbl and Rho-mediated
biology and provides evidence that Dbl proteins may regulate
cellular Rho functions as they relate to the activation of nuclear
signaling pathways. However, it remains a persistent question
why the transforming potency of Dbl family members often far
exceeds that of activated derivatives of their putative GTPase
targets. One possibility is that some Dbl proteins may coordi-
nate the activity of multiple Rho-dependent signaling path-
ways in vivo, the effects of which synergize to produce the
transformed phenotype. Alternatively, Dbl family proteins may
possess biological activities other than guanine nucleotide ex-
change, and thus may coordinate the activity of multiple Rho-
dependent and -independent signaling pathways.
It has also become apparent from this current study that the
in vitro GEF specificity that is assigned to Dbl family proteins
is not always predictive of in vivo signaling activity. For exam-
ple, whereas the Ect2 protein failed to exhibit any measurable
GEF activity when tested against a panel of Rho family GT-
Pases (11), we have observed focus morphology and signaling
activity associated with the Ect2 protein that indicates in vivo
activation of Rho-related proteins. In addition, we have ob-
served that Ect2 expression can bring about changes in the
actin cytoskeleton (lamellipodia and actin stress fiber forma-
tion) that are consistent with the activation of multiple Rho
family members, in particular RhoA and Rac1. Similarly, al-
though the Lfc protein forms complexes with both the Rac1 and
RhoA proteins (29), it only catalyzes exchange on RhoA in an in
vitro assay. However, the signaling data for Lfc, and the effects
of its expression on the actin cytoskeleton, are consistent with
the in vivo activation of both RhoA and either Rac1 or a Rac1-
related protein. Taken together, these results indicate that
some Dbl family proteins may have a broader range of in vivo
GEF activity than their in vitro specificity implies. One expla-
nation for this finding is that in vivo exchange activity may be
regulated by lipid or other cofactors, as was recently shown to
be the case for Tiam 1.3 Alternatively, it is also possible that
Dbl family proteins could stimulate additional Rho-regulated
signaling pathways through biological activities other than
guanine nucleotide exchange.
Specific Rho family proteins have been implicated as key
signaling molecules that are required for oncogenic Ras trans-
forming activity (24). Dominant negative mutants of Rho, Rac,
and CDC42Hs have been shown to impair Ras transforming
activity, presumably via their ability to form inactive com-
plexes with specific Dbl family proteins, and it is generally
assumed that Ras activation of Dbl family proteins will provide
the link(s) with Rho family proteins (32–35, 60). This possibil-
ity is supported by genetic studies in Schizosaccharomyces
pombe where a yeast Dbl family protein (Scd1) has been de-
fined that links Ras with a Rho family protein (cdc42Sp) (70).
Although it is still not clear whether oncogenic Ras activates
Rho family proteins via distinct signaling pathways, or by
stimulating cascades of Rho proteins, in either scenario, it is
likely that multiple Dbl family members will be involved. The
determination of which mammalian Dbl family proteins are
activated by oncogenic Ras activation will establish a key com-
ponent of the signaling pathways that link Ras with Rho family
proteins.
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